Ann: 2017 AGM Chairman's Address, page-3

Following the announcement of the Rett syndrome study results in March, Neuren has continued to receive a wide level of interest in the trofinetide programs from pharmaceutical companies around the world. We have nevertheless formed a view that partnering options are better considered once Neuren has met with the FDA. As always, the Board is guided by two important principles, these being, speed to market for the families affected by these conditions and maximising the commercial value to Neuren and our many shareholders who ultimately make this important work possible.

At least deal timing is now clear.